New product notice
AstraZeneca is pleased to announce that BRILINTA (ticagrelor) is now available for
BRILINTA (ticagrelor), co-administered with acetylsalicylic acid (ASA), is indicated for
the secondary prevention of atherothrombotic events in patients with Acute Coronary
Syndromes (ACS), including:
• Unstable angina (UA)
• Non-ST elevation myocardial infarction (NSTEMI)
• ST elevation myocardial infarction (STEMI)
Who are to be:
• Managed medically
• Managed with percutaneous coronary intervention (PCI), with or without stent
• Managed with coronary artery bypass graft (CABG)
Based on a relationship observed in PLATO between maintenance ASA dose and relative
efficacy of BRILINTA compared to clopidogrel, BRILINTA is recommended to be
co-administered with a low maintenance dose ASA (75-150 mg daily).
BRILINTA is available as 90 mg tablets
||90 mg blister compliance pack
||6 20641 014473
|Unit of sale
||1 x 60 tab pack (4 x 15 tab blisters)
The recommended daily dosage of BRILINTA is as follows:
*Unless specifically contraindicated
For further product or medical information enquiries, you may contact the Medical
Information Department by:
BRILINTA is contraindicated in patients who: are hypersensitive to this medication or to any ingredient in
the formulation, have active pathological bleeding such as peptic ulcer or intracranial hemorrhage, have a
history of intracranial hemorrhage, have moderate to severe hepatic impairment and/or are also taking
strong CYP3A4 inhibitors.
BRILINTA should be used with caution in patients with a propensity to bleed (e.g., due to recent trauma, recent
surgery, active or recent gastrointestinal bleeding or moderate hepatic impairment) and in patients requiring oral
anticoagulants (e.g., warfarin) and/or fi brinolytics agents (within 24 hours of BRILINTA dosing). Caution should also
be used in patients with concomitant administration of medicinal products that may increase the risk of bleeding
(e.g., non-steroidal anti-infl ammatory drugs [NSAIDs]). Co-administration of BRILINTA and a high maintenance
dose ASA (>150 mg daily) is not recommended.
In the PLATO study, bleeding events associated with BRILINTA were 11.6% total major and 16.1% combined
total major + minor. The most common adverse events associated with BRILINTA were dyspnea (12.0%),
headache (6.5%) and nosebleed (6.0%).
See the Product Monograph for full contraindications, warnings, precautions, dosing and administration.
Senior Marketing Manager - BRILINTA (ticagrelor)
Reference: 1. BRILINTA® Product Monograph. AstraZeneca Canada Inc. May 26, 2011.
BRILINTA® and the AstraZeneca logo are registered trademarks
of the AstraZeneca group of companies. © AstraZeneca 2011
AstraZeneca Canada Inc.
1004 Middlegate Road, Mississauga, Ontario, Canada L4Y 1M4
www.astrazeneca.ca TEL (905) 277-7111 FAX (905) 270-3248